Glycoprotein platelet inhibitors

What are Glycoprotein platelet inhibitors?

Glycoprotein platelet inhibitors prevent platelet adhesion by binding to the glycoprotein IIb/IIIa receptors on the plasma membrane of platelets. They stop the actual substrates of the glycoprotein receptors from binding to the receptor, so inhibit platelets from sticking together to form a thrombus, which can lead to stroke, myocardial infarction or deep vein thrombosis.

Glycoprotein platelet inhibitors are used in patients with angina, after a heart attack, angioplasty or other types of coronary vasculature procedures.

Glycoprotein IIb/IIIa inhibitors

abciximab (abcixifiban) (ReoPro)
eptifibatide (Integrilin)
tirofiban (Aggrastat)
roxifiban.
orbofiban.

Glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors prevent platelet aggregation by blocking glycoprotein IIb/IIIa receptors on their platelet’s plasma membrane and inhibiting fibrinogen binding. The available GP IIb/IIIa inhibitors include tirofiban and eptifibatide.

The glycoprotein IIb-IIIa inhibitors are the monoclonal antibody abciximab, the cyclic heptapeptide eptifibitide, and the nonpeptide small molecule agent tirofiban. The mechanism of action is blockade of the platelet glycoprotein IIb-IIIa fibrinogen receptor with resultant inhibition of platelet aggregation.